Compare IMMP & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | ATOS |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 25.9M |
| IPO Year | 2012 | 2010 |
| Metric | IMMP | ATOS |
|---|---|---|
| Price | $3.36 | $1.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 30.6K | ★ 48.0K |
| Earning Date | 09-01-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $0.53 |
| 52 Week High | $5.36 | $7.56 |
| Indicator | IMMP | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 28.30 |
| Support Level | $3.06 | N/A |
| Resistance Level | $3.55 | $2.60 |
| Average True Range (ATR) | 0.34 | 0.16 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 41.09 | 5.46 |
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.